PharmaLive: Athersys Begins Phase I Trial for ATHX-105 for Treatment of Obesity Milestone for Company's Lead Program in Emerging Clinical Pipeline

PharmaLive: Athersys Begins Phase I Trial for ATHX-105 for Treatment of Obesity Milestone for Company's Lead Program in Emerging Clinical Pipeline: "CLEVELAND, July 25, 2007 /PRNewswire-FirstCall/ -- Athersys, Inc., a wholly owned subsidiary of BTHC VI , announced today that it has initiated a Phase I clinical trial in the United Kingdom for ATHX-105, the company's oral, selective 5HT2c receptor agonist for treating obesity."